Your browser doesn't support javascript.
loading
GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
Morrison, Leigh; Gabison, Jonathan; Oshman, Lauren.
Afiliação
  • Morrison L; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO). morrisol@med.umich.edu.
  • Gabison J; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO).
  • Oshman L; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO).
J Am Board Fam Med ; 37(3): 372-382, 2024.
Article em En | MEDLINE | ID: mdl-39142859
ABSTRACT
The landscape of diabetes management has changed, such that the goal of pharmacotherapy extends beyond glucose-lowering to prioritize risk reduction of cardiovascular disease and diabetic kidney disease. Two newer classes of medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-Is), have become first line therapies for many patients with type 2 diabetes to reduce cardiovascular and renal complications of type 2 diabetes. This review article will describe the mechanism of action, evidence for cardiovascular and kidney outcomes, contraindications, adverse effects, and risk mitigation strategies for the GLP-1 RA and SGLT2-I drug classes. In addition, we will provide a practical approach for primary care clinicians to prescribe, adjust, and combine these medication classes, while considering patient preference, tolerability, comorbidities, cost, and availability.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose / Hipoglicemiantes Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose / Hipoglicemiantes Idioma: En Ano de publicação: 2024 Tipo de documento: Article